Amphetamine-Related Disorders Clinical Trial
Official title:
Extended-Release Naltrexone (XR-NTX, VIVITROL) for the Treatment of Actively-Using Methamphetamine-Dependent Men Who Have Sex With Men
Extended-release naltrexone (XR-NTX, VIVITROL) is an FDA-approved medication with efficacy in treating alcohol dependence and prevention of relapse to opioid dependence. It has shown promise in reducing relapse to amphetamine use among amphetamine-dependent, yet currently amphetamine-abstinent heterosexuals. The investigators will expand upon this promising work to determine whether monthly intramuscular injections of naltrexone will reduce methamphetamine (meth) use among actively using, meth-dependent men who have sex with men (MSM) in this double-blind randomized controlled trial of extended-release naltrexone versus placebo. The investigators will focus on MSM because of the disproportionate and intertwining epidemics of meth use and HIV in this population.
The investigators will enroll 100 sexually active, meth-dependent MSM who will be randomized 1:1 to receive monthly injections of extended-release naltrexone (n=50) or placebo (n=50) for 12 weeks at weeks 0, 4, and 8. Study participants will be seen weekly at our site at the HIV Prevention Section of the San Francisco Department of Public Health, where they will provide urine for drug testing and participate in substance use counseling. All participants will receive HIV risk-reduction counseling. Behavior will be assessed using standardized measures via audio computer-assisted self-interview (ACASI). ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02232789 -
Abuse Liability and Human Pharmacology of Mephedrone
|
Phase 1 | |
| Completed |
NCT00247572 -
Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories
|
Phase 2 | |
| Active, not recruiting |
NCT00100074 -
To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1
|
Phase 1 | |
| Active, not recruiting |
NCT00033072 -
Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1
|
Phase 1 | |
| Recruiting |
NCT06145698 -
Treatment Effect of Cross-frequency Transcranial Alternating Current Stimulation on the MUD
|
N/A | |
| Completed |
NCT00990067 -
Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)
|
Phase 1 | |
| Completed |
NCT02797990 -
Conflict Between Maternal Autonomy and Child Health in Substance-use
|
N/A | |
| Recruiting |
NCT01899313 -
A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence
|
N/A | |
| Active, not recruiting |
NCT00265278 -
Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1
|
Phase 1 | |
| Active, not recruiting |
NCT00000350 -
Effects of Stimulant Dependence on Human Striatal Dopamine System - 15
|
Phase 1 | |
| Active, not recruiting |
NCT00089440 -
Assessment of Interactions Between Methamphetamine and Aripiprazole - 1
|
Phase 1 | |
| Active, not recruiting |
NCT00040040 -
Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1
|
Phase 1 | |
| Completed |
NCT00040053 -
Ondansetron for the Treatment of Methamphetamine Dependence - 1
|
Phase 2 | |
| Completed |
NCT00895804 -
Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)
|
Phase 1 | |
| Recruiting |
NCT03902405 -
Computerized Exercise to Alter Stimulant Approach Responses
|
N/A | |
| Recruiting |
NCT04982796 -
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
|
Phase 1/Phase 2 | |
| Completed |
NCT01386177 -
Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)
|
Phase 1 | |
| Completed |
NCT01136278 -
Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)
|
Phase 1 | |
| Completed |
NCT00069251 -
Bupropion for the Treatment of Methamphetamine Dependence - 1
|
Phase 2 | |
| Completed |
NCT01270672 -
Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA)
|
N/A |